- Home
- GLTO vs NXN Comparison
GLTO vs NXN Comparison
Compare GLTO & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLTO | NXN |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 47.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLTO | NXN |
|---|---|---|
| Price | $21.00 | $12.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 86.5K | 9.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $48.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $10.64 |
| 52 Week High | $38.33 | $12.45 |
Technical Indicators
Market Signals| Indicator | GLTO | NXN |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 53.37 |
| Support Level | $20.62 | $11.96 |
| Resistance Level | $38.33 | $12.11 |
| Average True Range (ATR) | 3.88 | 0.09 |
| MACD | -1.41 | -0.00 |
| Stochastic Oscillator | 3.84 | 72.73 |
Price Performance
Historical ComparisonAbout GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.